普罗布考联合瑞舒伐他汀对ACS的抗炎和抗氧化作用

Anti-inflammatory and antioxidant effects of probucol combined rosuvastatin on acute coronary syndrome

目的:观察普罗布考联合瑞舒伐他汀对急性冠脉综合征(ACS)患者的血脂、高敏C反应蛋白(hsCRP)、白介素-6(IL-6)、同型半胱氨酸(Hcy)和氧化型低密度脂蛋白(ox-LDL)水平的影响。方法:选择在我院心内科住院确诊为ACS患者226例,随机分为联合治疗组(113例,普罗布考联合瑞舒伐他汀治疗)和瑞舒伐他汀组(113例);治疗时间为3个月。比较两组患者治疗前后血脂、hsCRP、IL-6、Hcy和ox-LDL水平的差异。结果:两组患者治疗3个月后血清总胆固醇(TC)、低密度脂蛋白-胆固醇(LDL-C)、甘油三酯(TG)、hsCRP、IL-6、ox-LDL和Hcy水平均较治疗前显著降低(P<0.05或<0.01),且与瑞舒伐他汀组比较,联合治疗组治疗后TC[(4.81±0.62)mmol/L比(4.02±0.53)mmol/L]、LDL-C[(2.35±0.52)mmol/L比(1.82±0.48)mmol/L]、hsCRP[(4.15±1.56)mg/L比(3.27±1.74)mg/L]、IL-6[(82.15±8.02)ng/L比(75.18±7.98)ng/L]、ox-LDL[(481.21±59.21)μg/L比(402.43±45.32)μg/L]和Hcy[(13.85±4.27)μmol/L比(10.29±3.87)μmol/L]水平下降更显著(P均<0.05)。结论:普罗布考联合瑞舒伐他汀较单纯瑞舒伐他汀治疗对急性冠脉综合征患者的抗炎、抗氧化作用更强。

Objective：To obverse influence of probucol combined rosuvastatin on levels of blood lipids,high sensitive C reactive protein（hsCRP）,interleukin-6（IL-6）,homocysteine（Hcy）and oxidized low density lipoprotein（ox-LDL）in patients with acute coronary syndrome（ACS）.Methods：A total of 226 patients who were hospitalized in our department of cardiology and diagnosed as ACS were selected.They were randomly and equally divided into rosuvastatin group and combined treatment group（received probucol combined rosuvastatin treatment）,both groups were treated for three months.Levels of blood lipids,hsCRP,IL-6,Hcy and ox-LDL were compared between two groups before and after treatment.Results：Compared with before treatment,there were significant reductions in serum levels of total cholesterol（TC）,low density lipoprotein cholesterol（LDL-C）and triglyceride（TG）,levels of hsCRP,IL-6,ox-LDL and Hcy in both groups after three months,P〈0.05or0.01.Compared with rosuvastatin group after treatment,there were significant reductions in levels of TC [（4.81±0.62）mmol/L vs.（4.02±0.53）mmol/L],LDL-C [（2.35±0.52）mmol/L vs.（1.82±0.48）mmol/L],hsCRP[（4.15±1.56）mg/L vs.（3.27±1.74）mg/L],IL-6 [（82.15±8.02）ng/L vs.（75.18±7.98）ng/L],ox-LDL [（481.21±59.21）μg/L vs.（402.43±45.32）μg/L]and Hcy[（13.85±4.27）μmol/L vs.（10.29±3.87）μmol/L]in combined treatment group,P〈0.05 all.Conclusion：Compared with pure rosuvastatin,probucol combined rosuvastatin therapy possesses stronger anti-inflammatory and antioxidant effect in patients with acute coronary syndrome.